HoldsUp

FoundMyFitness · 2026-07-22 · Rhonda Patrick (host), Derya Unutmaz

Why the Next 10 Years May Add 50 to Your Lifespan | Dr. Derya Unutmaz

42 research-tied claims examined: 2 contradicted 3 overstated 4 context 29 supported 2 corroborated online 2 unverified

2

Contradicted by research

0:22:15Derya Unutmazcontradictedhigh

Humans did not have language until approximately 10,000 years ago, and writing and cognitive intelligence developed only in the last 10,000 to 20,000 years.

"We didn't have language up to, I don't know, 10,000 years ago; we didn't know how to write. This cognitive part has developed in the last maybe 10, 20,000 years." (said at 0:22:15)

The claim that humans did not have language until approximately 10,000 years ago and that cognitive intelligence only emerged in the last 10,000 to 20,000 years is contradicted by archaeological, paleoanthropological, and genetic consensus. Anatomically and cognitively modern *Homo sapiens* evolved over 100,000 to 300,000 years ago in Africa, displaying complex symbolic behavior, tool manufacturing, and language capacities tens to hundreds of thousands of years before the 10,000-year mark (for example, language and complex cognitive capacities were already established prior to human migrations out of Africa and the peopling of Australia at least 50,000 to 65,000 years ago). While the speaker's secondary mention that writing was absent prior to recent millennia is accurate (true writing systems first emerged around ~5,000 to 5,500 years ago in Mesopotamia and Egypt), spoken language and human cognitive capacities long predate the 10,000-to-20,000-year timeline.

1:10:55Derya Unutmazcontradictedhigh

Only about 1 in 5 to 1 in 10 people who take statins for high cholesterol derive a true cardiovascular benefit.

"we give statins to anyone who has high cholesterol. So I I think like one out of five or one out of 10 people truly benefit from that." (said at 1:10:55)

Large-scale systematic reviews and meta-analyses of randomized clinical trials show that for primary prevention of cardiovascular disease, statins reduce composite cardiovascular outcomes by an absolute risk difference (ARD) of approximately 1.28% over 1 to 6 years of follow-up (equating to roughly 1 in 78 individuals avoiding an event, or a Number Needed to Treat [NNT] of ~78). For myocardial infarction, the ARD is 0.85% (NNT ~118), and for all-cause mortality, it is 0.35% (NNT ~285). The claim that 1 in 5 (20%) to 1 in 10 (10%) individuals derive a true cardiovascular benefit substantially overestimates the absolute proportion of patients who avoid a major cardiovascular event over typical trial durations, which is closer to 1% to 2% (1 in 50 to 1 in 100).

3

Overstated

0:05:15Derya Unutmazoverstatedmoderate

GLP-1 receptor agonists add approximately 5 to 10 years to the lifespan of people who are obese or have chronic conditions.

"Or we're already starting to see that with the GLP-1 drugs, receptor agonists, which are adding about 5 to 10 years to the lifespan of people who are obese or who have chronic conditions." (said at 0:05:15)

GLP-1 receptor agonists (such as semaglutide and liraglutide) have been shown in large randomized clinical trials to significantly reduce all-cause mortality and major adverse cardiovascular events in individuals with obesity, diabetes, and established cardiovascular disease. However, the claim that they add 5 to 10 years to lifespan is substantially overstated. Actuarial modeling applying trial data (such as from the SELECT trial) to real-world populations projects average life expectancy gains of approximately 1.9 years (and ~2.0 cardiovascular event-free years), rather than 5 to 10 years.

0:16:26Derya Unutmazoverstatedlow

Self-driving cars are currently about 10 times safer than human drivers.

"And right now, self-driving cars are probably about 10 times safer, they will be maybe 100 times safer" (said at 0:16:26)

The speaker claims that self-driving cars are currently "about 10 times safer" than human drivers. Real-world safety assessments of fully autonomous vehicles (such as Waymo's Rider-Only operations) show statistically significant reductions in crash and injury rates compared to human benchmarks, but not by a factor of 10. For example, analysis of 7.14 million miles of Waymo autonomous driving reported an 80% reduction in any-injury-reported crash rates (a human crash rate 5 times higher, or ADS 5 times safer) and a 55% reduction in police-reported crash rates (2.2 times higher human rate). Analysis across 56.7 million miles demonstrated significant reductions across crash types (such as a 91% to 96% reduction in specific vehicle-to-vehicle intersection crashes), but overall safety across all conditions and operations is not 10 times safer than human drivers. Thus, the claim overstates the current safety advantage.

2:06:33Derya Unutmazoverstatedhigh

Partial epigenetic reprogramming clinical trials are being conducted in patients with glaucoma.

"Like this partial reprogramming trial they're doing, it's it's done for glaucoma patients, I I guess, uh, because that happens in old age, right?" (said at 2:06:33)

The claim that partial epigenetic reprogramming clinical trials are currently being conducted in human patients with glaucoma overstates the clinical progress of this research. Partial epigenetic reprogramming (using Oct4, Sox2, and Klf4, or OSK gene therapy) has shown success in restoring vision in animal models (mice and non-human primates) of glaucoma and optic nerve injury. However, as of recent reviews, these therapies remain in preclinical development, and human clinical trials in glaucoma patients have not yet been conducted.

4

Needs context

0:42:31Derya Unutmazneeds contextmoderate

AI models can detect certain tumors like breast cancer years before a radiologist can see them.

"The AI models are able to detect certain tumors like breast cancer years before a radiologist is able to to to see that." (said at 0:42:31)

Deep learning models (such as Mirai) have been developed and validated to evaluate screening mammograms read as negative by radiologists to predict the future risk of breast cancer up to 1 to 5 years in advance (achieving concordance indices of approximately 0.75–0.84 across diverse international cohorts). However, these algorithms are assessing imaging-based future risk and parenchymal features rather than directly visualizing or detecting an established, measurable tumor years before clinical diagnosis.

1:10:20Derya Unutmazneeds contextmoderate

COVID-19 vaccination caused myocarditis in young people at a rate of 1 in 5,000 to 1 in 10,000.

"Yes, the vaccinated people, young people, at 1 in 5,000 to 1 in 10,000 rate got myocarditis." (said at 1:10:20)

A rate of 1 in 5,000 to 1 in 10,000 (equivalent to 100 to 200 cases per million) falls within the estimated peak incidence range for the highest-risk subgroup—specifically adolescent and young adult males (aged 12–29) following a second mRNA vaccine dose (especially with mRNA-1273 or shorter interdose intervals). However, attributing this rate to "young people" in general requires qualification, as the incidence is significantly lower in young females (fewer than 20 cases per million, or <1 in 50,000) and across all young vaccinees when combining both sexes and all doses.

1:42:08Derya Unutmazneeds contexthigh

Dolly the sheep, cloned in the late 1990s, was the first cloned sheep.

"The first moment was, uh, the, um, the sheep, uh, that's called Dolly. Uh, you probably know it was the first cloned sheep. Um, it was 1996, '97, or something like that." (said at 1:42:08)

The claim is partially accurate but requires qualification. Dolly the sheep, born in July 1996 (with results published in 1997), was famously the first mammal cloned from an *adult somatic cell* (specifically, a mammary gland cell). However, she was not the first cloned sheep. Cloned sheep had been produced a decade earlier in 1986 by Steen Willadsen using nuclear transfer from embryonic blastomeres. Dolly's scientific breakthrough was demonstrating that an adult differentiated somatic cell nucleus could be reprogrammed to control full embryonic development.

  • context: Science and technology of farm animal cloning: state of the art. (Animal reproduction science 2006) · cited 109x in the literature
    "Details of the first mammal born after nuclear transfer cloning were published by Steen Malte Willadsen in 1986. In spite of its enormous scientific significance, this discovery failed to trigger much public concern, possibly because the donor cells were derived from pre-implantation stage embryos. The major breakthrough in terms of public recognition has happened when Ian Wilmut et al. [Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J., Campbell, K.H., 1997. Viable offspring derived from fetal és adult mammalian cells. Nature 385, 810-813] described the successful application of almost exactly the same method, but using the nuclei of somatic cells from an adult mammal, to create Dolly the sheep." (abstract, passage verified)
    pubmedfull study (doi)
  • context: Nuclear transfer in ruminants. (Methods in molecular biology (Clifton, N.J.) 2015) · cited 4x in the literature
    "Ruminants were the first mammalian species to be cloned successfully by nuclear transplantation. Those experiments were designed to multiply high merit animals (Willadsen, Nature 320(6057):63-65, 1986; Prather et al., Biol Reprod 37(4):859-866, 1987; Wilmut et al., Nature 385(6619):810-813, 1997)." (abstract, passage verified)
    pubmedfull study (doi)
2:02:55Derya Unutmazneeds contextmoderate

Epigenetic aging clocks measured in blood largely reflect the proportion of differentiated effector T cells accumulating in old age versus naive T cells.

"Usually they're done through through blood analysis, but in the blood you have, uh, like, you know, I work with T cells, so you have these cells that we call effector cells that have, um, lots of epigenetic change because they differentiated and they continue to accumulate in in old age. And then you have these naive cells that have, you know, more pristine, uh, kind. So it's a combination. So depending on, um, what that combination is is going to affect the output of of the, um So you you you can actually just look at the proportion of your, uh, T cell differentiated T cells, you'll probably get the same same kind of information." (said at 2:02:55)

Blood-based epigenetic clocks are significantly influenced by age-associated shifts in immune cell composition, particularly the decline in naive T cells and accumulation of differentiated effector memory T cells. Purified naive CD8+ T cells score 15 to 20 years younger by epigenetic clocks than effector memory CD8+ T cells from the very same donor. However, claiming that clocks solely or largely reflect cell proportions overstates the case: isolated, homogenous naive T cells still show progressive epigenetic aging as donors age, demonstrating that standard blood epigenetic clocks capture two independent phenomena simultaneously: cell-intrinsic epigenetic aging and changing leukocyte subset composition.

29

Supported by research

0:19:44Derya Unutmazsupportedhigh

AI defeated chess champion Garry Kasparov in 1997.

"AI beat the chess champion Kasparov in 1997, I think, decades ago, but that was not general intelligence." (said at 0:19:44)

IBM's Deep Blue chess system defeated reigning world chess champion Garry Kasparov in a six-game match held in May 1997 in New York. The system used specialized hardware, tree search algorithms, and domain-specific heuristics rather than artificial general intelligence.

0:02:54Derya Unutmazsupportedhigh

The term 'longevity escape velocity' was coined by biogerontologist Aubrey de Grey.

"So we will get to a point what's called the longevity escape velocity. This was coined by Aubrey de Grey, who, as you know, is a great aging researcher." (said at 0:02:54)

Biogerontologist Aubrey de Grey is widely documented in the scientific and bioethics literature as the originator of the concept of 'longevity escape velocity' (the hypothetical threshold where anti-aging biomedical interventions extend life expectancy faster than time passes). De Grey, who formulated the Strategies for Engineered Negligible Senescence (SENS) framework, identifies as a biomedical gerontologist and introduced the concept in discussions of radical life extension and aging repair.

0:19:10Derya Unutmazsupportedhigh

The AI program AlphaGo defeated the world champion in the board game Go.

"Or AlphaGo beat the world champion in Go, which is a much more difficult game." (said at 0:19:10)

The claim is supported by published literature on artificial intelligence and game theory. Google DeepMind's AlphaGo defeated top-ranked human Go world champion Lee Sedol 4–1 in March 2016 and world champion Ke Jie in May 2017. Go was long considered a major benchmark for artificial intelligence due to its vast decision space and extreme combinatorial complexity relative to games such as chess.

0:41:50Derya Unutmazsupportedmoderate

In the United States, there are approximately 12 million medical misdiagnoses each year, resulting in around 700,000 people dying or suffering from harm.

"I think they've said something like 12 million misdiagnosis. Um I think 700,000 people suffer from it, die from it, from from uh uh from misdiagnosis." (said at 0:41:50)

The speaker accurately cites landmark epidemiological estimates of diagnostic errors in the United States. A 2014 study by Singh and colleagues synthesized data across outpatient observational cohorts and estimated that diagnostic errors affect approximately 5.08% of US adults, representing approximately 12 million individuals annually. A subsequent 2024 nationwide modeling study by Newman-Toker and colleagues estimated that misdiagnoses result in approximately 795,000 cases of permanent disability or death each year (plausible range: 598,000 to 1,023,000).

0:59:30Rhonda Patrick (host)supportedhigh

Cardiovascular disease is the leading cause of death in most developed countries.

"cardiovascular disease being the number one killer in in most developed countries." (said at 0:59:30)

Large-scale epidemiological studies, including the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), confirm that cardiovascular diseases (primarily ischemic heart disease and stroke) represent the leading cause of mortality and disease burden globally and across high-income and developed countries.

1:00:32Derya Unutmazsupportedhigh

Certain childhood leukemias that were previously fatal now have cure rates between 90% and close to 100%.

"childhood leukemias, which were completely fatal, you know, couple of decades ago, are now, you know, 90% or or close to 100% curable." (said at 1:00:32)

Childhood acute lymphoblastic leukemia (ALL), which was universally fatal prior to modern multi-agent chemotherapy regimens developed in the mid-to-late 20th century, now demonstrates long-term survival and cure rates approaching or exceeding 90% in contemporary treatment protocols.

1:16:40Derya Unutmazsupportedhigh

There are more than 1,000 metabolites present in the human bloodstream.

"there are more than a thousand metabolites in our bloodstream" (said at 1:16:40)

The claim is supported. Systematic profiling of the human serum metabolome using multi-platform analytical technologies (NMR, GC-MS, and LC-MS) and literature curation has identified thousands of distinct metabolites present in human blood. The Human Serum Metabolome Project documented over 4,200 confirmed and highly probable compounds in human serum.

  • supports: The human serum metabolome. (PloS one 2011) · cited 1735x in the literature
    "Tables containing the complete set of 4229 confirmed and highly probable human serum compounds, their concentrations, related literature references and links to their known disease associations are freely available at http://www.serummetabolome.ca." (abstract, passage verified)
    pubmedfull study (doi)
1:17:22Rhonda Patrick (host)supportedmoderate

AstraZeneca developed an AI model named Milton using UK Biobank plasma protein data to accurately predict cancer and neurodegenerative diseases up to 10 years before onset.

"I think the model was called Milton or something, and AstraZeneca developed it or something. And I remember looking at this study because, like you mentioned, the Biobank data is a huge data set, and it's spanning many decades. And so I think they looked at, you know, like over 200 plasma proteins. You're talking about 10; we're talking about 200, right? And all the other data, right? And they were able to predict—and I think cancer and neurodegenerative disease were at the top of like 10 years before" (said at 1:17:22)

AstraZeneca developed an ensemble machine-learning tool named MILTON (Machine Learning with Phenotype Associations) using UK Biobank multi-omics, clinical biomarkers, and plasma proteomics data (from over 46,000 individuals) to predict thousands of incident diseases, including cancers and neurodegenerative conditions, up to 10 or more years prior to clinical diagnosis.

  • supports: Disease prediction with multi-omics and biomarkers empowers case-control genetic discoveri… (Nature genetics 2024) · cited 109x in the literature
    "Here, we present an ensemble machine-learning framework (machine learning with phenotype associations, MILTON) utilizing a range of biomarkers to predict 3,213 diseases in the UK Biobank. Leveraging the UK Biobank's longitudinal health record data, MILTON predicts incident disease cases undiagnosed at time of recruitment, largely outperforming available polygenic risk scores. We further demonstrate the utility of MILTON in augmenting genetic association analyses in a phenome-wide association study of 484,230 genome-sequenced samples, along with 46,327 samples with matched plasma proteomics data." (abstract, passage verified)
    pubmedfull study (doi)
1:24:45Derya Unutmazsupportedhigh

Children with progeria age prematurely to resemble 80- or 90-year-olds by the age of 7 or 8 due to a single point mutation.

"there is a disease called progeria. These children get aged by the age of seven, eight; they become like an 80-, 90-year-old because of a single point mutation in one of their genes, because they lose their ability to repair" (said at 1:24:45)

The speaker's claim is supported by clinical genetics literature. Hutchinson-Gilford progeria syndrome (HGPS) is classically caused by a de novo heterozygous point mutation in the LMNA gene (most commonly c.1824C>T, p.Gly608Gly). This mutation activates a cryptic splice site producing a toxic truncated lamin A protein called progerin. Progerin disrupts the nuclear envelope, interferes with the DNA damage response and DNA repair mechanisms, and leads to dramatic accelerated physiological aging phenotypes (including severe cardiovascular disease, alopecia, lipodystrophy, and skin changes), giving affected children the physical appearance and cardiovascular pathologies typical of very advanced age by middle-to-late childhood.

1:13:59Rhonda Patrick (host)supportedhigh

The scientific framework for the biology of aging recognizes 12 distinct hallmarks of aging.

"We've got these 12 hallmarks of biology—we now have 12: genomic instability, mitochondrial dysfunction, you know, cellular senescence, on and on. We've got there's 12 of them." (said at 1:13:59)

The canonical scientific framework for the biology of aging, originally established in 2013 with 9 hallmarks, was updated in a landmark 2023 review in Cell (López-Otín et al.) to define 12 distinct hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis.

  • supports: Hallmarks of aging: An expanding universe. (Cell 2023) · cited 6257x in the literature
    "We propose the following twelve hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis." (abstract, passage verified)
    pubmedfull study (doi)
1:15:13Derya Unutmazsupportedhigh

Certain species of whales have lifespans reaching hundreds of years.

"For some whales, it's hundreds of years." (said at 1:15:13)

Scientific literature confirms that certain whale species, particularly the bowhead whale (Balaena mysticetus), can live for more than 200 years, making them the longest-lived mammals known.

1:32:30Derya Unutmazsupportedmoderate

Elephants rarely get cancer because they have multiple copies of the p53 gene, which acts as a guardian of the genome preventing mutations.

"Like elephants rarely get cancer, right? Because they have this gene called p53; they have multiple copies of that. p53 is kind of like the guardian of the genome. You know, it prevents the genome from getting too much mutations and prevents cancer. So somehow elephants have—I don't know how many copies, but they get very rarely cancer." (said at 1:32:30)

Comparative genomic and cellular studies confirm that elephants have a low incidence of cancer despite their large body size and long lifespan (an example of Peto's paradox). While humans carry one copy (2 alleles) of the TP53 tumor suppressor gene—often referred to as the guardian of the genome—African elephants possess at least 20 copies (40 alleles, including 19 retrogenes). These duplicated copies contribute to an enhanced DNA damage response and heightened p53-mediated apoptosis, which clears damaged cells and protects against cancer development.

1:33:00Derya Unutmazsupportedvery low

Naked mole-rats can live 30 to 40 years compared to regular rats that live only a couple of years, in part due to a mutation in the immune gene cGAS involved in immune optimization and DNA repair.

"Naked mole-rats, you probably know that very well, you know, they're like rats, they live underground, but normal rats live a couple of years and these guys live 30, 40 years. So it turns out they have some mutation in some immune gene called cGAS that's also involved in immune optimization and DNA repair." (said at 1:33:00)

Naked mole-rats (*Heterocephalus glaber*) are well-documented to have an exceptionally long lifespan exceeding 30 to 37 years, compared to typical laboratory and wild rats that live only 2 to 3 years. Research published in *Science* (2025) demonstrated that naked mole-rat cyclic GMP-AMP synthase (cGAS)—a classical innate immune DNA-sensing enzyme—harbors evolutionary amino acid alterations (a four-amino-acid difference compared to human and mouse homologs) that remove its normal suppressive effect on homologous recombination DNA repair. This unique cGAS variant enhances chromatin retention after DNA damage, promotes RAD50 recruitment to facilitate DNA double-strand break repair, antagonizes cellular senescence, and contributes to lifespan extension. Because the supporting evidence is derived from animal and mechanistic molecular biology models, the GRADE certainty is very low.

1:36:10Derya Unutmazsupportedhigh

TNF receptors can initiate either a survival signal or a cell death/suicide signal depending on the cellular context.

"like in the immune system, we have these receptors called TNF receptors or whatever, they can have a survival signal or a death signal, suicide signal, depending on the context of the cell." (said at 1:36:10)

Tumor necrosis factor (TNF) receptor signaling is a well-established molecular paradigm capable of driving either cell survival or programmed cell death (apoptosis or necroptosis), depending on the signaling complex assembled and downstream cellular context. Activation of TNFR1 triggers membrane-bound Complex I (involving TRADD, RIPK1, and TRAF2) to activate NF-κB and MAP kinase pathways, promoting pro-survival genes. If this initial survival response is compromised or modified, a secondary cytoplasmic complex (Complex II, containing FADD and caspase-8) forms to initiate apoptosis, or necroptosis if caspases are inhibited.

1:36:35Derya Unutmazsupportedvery low

If Yamanaka factors are active continuously, they can cause cancer and teratomas.

"these things called Yamanaka factors, where you can generate a stem cell from a normal cell, right? So like complete regeneration. But the problem is that they can also cause cancer, because they only need to be active in certain time. If they're active all the time, they can cause teratomas and things like that." (said at 1:36:35)

The speaker correctly states that continuous or unconstrained activation of the Yamanaka reprogramming factors (OCT4, SOX2, KLF4, and c-MYC) in vivo leads to tumor and teratoma formation. Seminal animal studies demonstrated that sustained induction of these four transcription factors in mice results in multi-organ teratomas and loss of cellular identity. Consequently, regenerative approaches rely on transient, cyclic, or partial reprogramming to achieve rejuvenation or tissue repair without inducing tumorigenesis. Because this body of evidence is established primarily in preclinical animal models and in vitro systems, the GRADE certainty is very low.

1:40:34Rhonda Patrick (host)supportedhigh

The oldest verified human lived to be 122 years old, a French woman.

"the oldest was like 121, maybe 122 French woman. I mean, the fact that right now we know that humans can at least live to be 122 is exciting." (said at 1:40:34)

Demographic and gerontological records confirm that the oldest thoroughly validated human lifespan on record belongs to Jeanne Calment, a French woman who died in 1997 at the age of 122 years and 164 days.

1:41:07Derya Unutmazsupportedmoderate

Only about 300 living people worldwide are supercentenarians aged 110 and older.

"only 300 people in the world are 110 and older. Why is that? Why not the rest of the 8 billion, right?" (said at 1:41:07)

Demographic and genomic studies of extreme longevity estimate that roughly 300 to 500 living supercentenarians (individuals aged 110 and older) exist worldwide at any given time. Because age validation requires extensive official documentation, only a fraction of this estimated total (typically around 50 to 100 individuals) are formally verified at a single point in time. For example, a 2014 study on supercentenarian genomics noted 74 validated living supercentenarians worldwide at the time of writing.

1:43:11Derya Unutmazsupportedhigh

The Yamanaka factors, which allow reprograming a somatic cell into an induced pluripotent stem cell, were discovered in 2006.

"And then the second, of course, uh, uh, the the Yamanaka factors, uh, in 2006, I think. Um, and that was the moment that, uh, that we knew, um, that we could completely erase the, um, sort of the age of the cell on a cellular level and then bring it back to a pluripotent stem cell level" (said at 1:43:11)

The discovery of induced pluripotent stem cells (iPSCs) and the four reprogramming transcription factors (OCT3/4, SOX2, KLF4, and c-MYC, collectively known as the Yamanaka factors) was published by Kazutoshi Takahashi and Shinya Yamanaka in 2006. This work demonstrated that differentiated somatic cells (such as mouse fibroblasts) could be reprogrammed back into a pluripotent stem cell state using a defined set of factors.

1:46:30Rhonda Patrick (host)supportedvery low

Juan Carlos Izpisua Belmonte conducted studies in progeria mice showing that partial cellular reprogramming rejuvenated certain organs and extended lifespan.

"I think it was like Juan Carlos, um, Izpisua, he he's now, I think, at Altos Labs, but he at the time was at the Salk Institute, and, um, he had done this in in mice. I think they were even maybe perhaps progeria mice, or some sort of accelerated aging model, and there was some reversal of, you know, certain organs seemed to be rejuvenated in a sense, and, um, the the life expectancy was extended in those animals." (said at 1:46:30)

The speaker's statement accurately describes a landmark 2016 study led by Juan Carlos Izpisua Belmonte's laboratory at the Salk Institute. The researchers demonstrated that cyclic, partial in vivo reprogramming using the Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc) ameliorated age-associated physiological hallmarks and extended lifespan in a transgenic mouse model of Hutchinson-Gilford progeria syndrome (premature aging), as well as improved tissue recovery in aged wild-type mice. Because this finding is based strictly on preclinical animal models, certainty is graded as very low.

1:52:00Derya Unutmazsupportedvery low

Jennifer Doudna's lab recently developed a new genome-editing tool for bacteria superior to standard CRISPR.

"Like, of course, we have CRISPR now, but actually Doudna's lab just came out with something even better for bacteria for genome editing." (said at 1:52:00)

Jennifer Doudna's laboratory, in collaboration with colleagues, developed DNA-editing all-in-one RNA-guided CRISPR-Cas transposase (DART) systems along with environmental transformation sequencing (ET-seq). Unlike standard CRISPR-Cas nucleases (such as Cas9), which generate double-strand breaks that are frequently lethal to bacteria lacking robust non-homologous end-joining pathways, DART leverages CRISPR-associated transposases (CASTs) to perform programmable, site-specific integration of large DNA cargos directly into targeted bacterial genomes within mixed microbial communities.

1:52:35Derya Unutmazsupportedhigh

Immune cells can be engineered in culture to perform biological logic operations such as AND, OR, and NOT gates based on specific molecular inputs.

"We can program immune cells in in in culture. Like we can give a a drug, it will shut down their response. Or we can create AND/OR gates and NOT gates: If they see two molecules, then they respond; if they see one, they don't." (said at 1:52:35)

Synthetic biology and cellular immunotherapy enable immune cells (such as CAR T cells) to be engineered in vitro with Boolean logic circuits (AND, OR, and NOT/INHIBIT gates) as well as drug-inducible safety switches. For instance, split-signaling CARs or synthetic Notch (synNotch) receptor systems can be designed as AND gates (requiring two target antigens to activate killing), inhibitory CARs (iCARs) function as NOT gates (suppressing activation if a healthy-tissue antigen is encountered), and multi-specific CARs act as OR gates (triggering killing if either antigen is present).

1:50:45Derya Unutmazsupportedhigh

Clinical trials in Japan have started using induced pluripotent stem cell technology derived from Yamanaka factors in human patients.

"In fact, I I think there was just a recent study that started in Japan using the Yamanaka factors, uh, uh, in in clinical trials because, you know, it was not a very controlled system." (said at 1:50:45)

Clinical studies and trials using induced pluripotent stem cell (iPSC) technology—originally discovered by Shinya Yamanaka using reprogramming transcription factors (Yamanaka factors)—have taken place in Japan. The first-in-human trial using autologous iPSC-derived cells was initiated in Japan for neovascular age-related macular degeneration (reported in 2017), where skin fibroblasts were reprogrammed into iPSCs and differentiated into retinal pigment epithelial sheets for transplantation. Subsequent trials in Japan have also commenced for conditions such as spinal cord injury and Parkinson's disease.

2:07:10Derya Unutmazsupportedmoderate

In old age, individuals accumulate CMV-specific T cells, which in some individuals can expand to occupy 20% to 30% of all T cells dedicated to a single CMV peptide.

"Like, for example, in old age you you accumulate these CMV-specific T cells. Um, CMV is a virus that you can't really get rid of, so the immune system constantly have to keep it under check. Um, and those immune cells, they kind of become like missionaries. They should retire, but they keep on expanding, and some individuals might have like 20, 30% of all their T cells just dedicated to like one peptide of this this CMV." (said at 2:07:10)

Human immunology studies demonstrate that latent cytomegalovirus (CMV) infection drives 'memory inflation' over a person's lifespan. In older adults, persistent immune surveillance against CMV leads to large clonal expansions of CD8+ T cells, where a massive fraction (often reaching up to 10% to >20-30% of circulating CD8+ T cells in specific individuals) is targeted against a single immunodominant CMV peptide epitope.

2:08:00Derya Unutmazsupportedmoderate

Accumulated CMV-specific T cells in older age are differentiated, have shorter telomeres, and are epigenetically closed.

"and they cause inflammation because they're they're active, and, um, and they don't give place for the young guys to come in. Uh, and they're they are epigenetically, you know, closed because, um, they're differentiated, their telomeres are shorter." (said at 2:08:00)

The statement accurately reflects established immunological findings on cytomegalovirus (CMV)-induced immunosenescence. Chronic CMV infection drives massive clonal expansion of CMV-specific CD8+ T cells (memory inflation), skewing the T-cell repertoire toward terminally differentiated effector memory (TEMRA/CD28-CD57+) phenotypes. Studies demonstrate that CMV-specific CD8+ T cells in older individuals exhibit significantly shorter telomeres due to repeated antigen-driven proliferation and undergo progressive epigenetic and transcriptional remodeling associated with terminal differentiation and cellular senescence.

2:01:20Derya Unutmazsupportedhigh

The UK Biobank collected biological and health data on 500,000 people.

"UK Biobank has done it for 500,000 people. You can do it for a million people." (said at 2:01:20)

The UK Biobank is a large prospective cohort study that recruited approximately 500,000 participants aged 40 to 69 across the United Kingdom. It collected extensive biological samples, physical and phenotypic measurements, lifestyle data, genetic information, and longitudinal health outcomes via medical record linkage.

  • supports: The UK Biobank resource with deep phenotyping and genomic data. (Nature 2018) · cited 10015x in the literature
    "The UK Biobank project is a prospective cohort study with deep genetic and phenotypic data collected on approximately 500,000 individuals from across the United Kingdom, aged between 40 and 69 at recruitment. The open resource is unique in its size and scope. A rich variety of phenotypic and health-related information is available on each participant, including biological measurements, lifestyle indicators, biomarkers in blood and urine, and imaging of the body and brain." (abstract, passage verified)
    pubmedfull study (doi)
2:02:50Derya Unutmazsupportedmoderate

Multiple studies demonstrate that higher levels of optimism improve aging outcomes and longevity.

"By the way, being optimistic is one of the best things you can do for for aging, and study after study show that. So being able to absorb, um, bad things that happen to you and then keep keep going. So resilience." (said at 2:02:50)

Multiple large prospective cohort studies and meta-analyses consistently show that higher levels of dispositional optimism are associated with improved aging outcomes, reduced all-cause mortality, and increased longevity. A 2019 meta-analysis of prospective cohort studies involving 229,391 participants found that optimism was significantly associated with a lower risk of all-cause mortality (RR 0.86, 95% CI 0.80–0.92) and cardiovascular events (RR 0.65, 95% CI 0.51–0.78). Furthermore, analyses from the Nurses' Health Study and the Veterans Affairs Normative Aging Study demonstrated that individuals in the highest versus lowest optimism quartiles had an 11% to 15% longer lifespan and 1.5- to 1.7-fold greater odds of reaching exceptional longevity (age 85 or older), associations that persisted after adjusting for health behaviors and baseline medical conditions.

2:16:20Rhonda Patrick (host)supportedhigh

Brain-derived neurotrophic factor (BDNF) plays an active role in enhancing neuroplasticity and stimulating the generation of new neurons.

"if we can increase brain-derived neurotrophic factor, some of these things that we know does play a role in improving neuroplasticity and, you know, and growing new neurons" (said at 2:16:20)

Extensive neurobiological and translational evidence confirms that brain-derived neurotrophic factor (BDNF) acts through its high-affinity receptor, tropomyosin receptor kinase B (TrkB), to regulate synaptic transmission, enhance synaptic plasticity and synaptogenesis, and promote adult neurogenesis (the generation and survival of new neurons), particularly within the hippocampus.

2:33:22Derya Unutmazsupportedhigh

Standard clinical laboratory reference ranges for biomarkers like cholesterol, glucose, and sodium are determined based on population averages rather than individualized baselines.

"For example, the lab values, like you go and measure your cholesterol, glucose, sodium, whatever, they always give you a range, right? So if it's within this range, it's normal. Well, how do you know that? Because you can be at the top of the range, that might be your abnormal, somebody else's normal. Somebody might be a little bit over the normal and might still be okay, or vice versa, because we don't know the level on a personalized level. So we calculate population-based." (said at 2:33:22)

Standard clinical laboratory reference intervals (ranges) for routine biochemical markers are conventionally established from healthy reference populations (typically encompassing the central 95% of values in a reference sample group), rather than personalized baselines. Because within-subject biological variation is often narrower than between-subject population variation (demonstrated by low index of individuality for many routine analytes such as lipids and liver enzymes), an individual's personal baseline range is typically narrower than standard population-based reference intervals.

2:34:45Derya Unutmazsupportedhigh

Continuous glucose monitors collect data at 5-minute intervals.

"With continuous glucose meter, I collect it every 5 minutes." (said at 2:34:45)

Commercial real-time continuous glucose monitoring (CGM) systems routinely measure and record interstitial glucose concentrations at 5-minute intervals, transmitting updated glucose values and trend indicators to a receiver or smartphone.

2

Corroborated by web sources

1:07:38Derya Unutmazcorroborated (web)

An Australian computer scientist used AI models including ChatGPT to design an individualized mRNA vaccine that caused tumor regression in his dog diagnosed with melanoma.

"You probably heard of this story from Australia. This computer scientist um had ChatGPT and and some other AI models to develop an mRNA vaccine for his dog. His dog had I think a melanoma, and he um he got it sequenced. He took the sequence and gave it gave it to to an AI model, and the AI model designed the precise mRNA molecule that needs that the dog needs dog's immune system needs to be trained, got it synthesized, and I think it was able to apply it in 3 months. Um probably could have been shorter if there wasn't regulations, and and the tumor started to to regress, and the dog is was was alive when it was supposed to to die." (said at 1:07:38)

No published record matching the case of an Australian computer scientist using ChatGPT or other AI models to design a personalized mRNA vaccine that induced tumor regression in a dog with melanoma was located; this does not prove the claim false.

corroborated by web sources

Australian tech entrepreneur Paul Conyngham utilized AI tools, including ChatGPT and AlphaFold, alongside researchers at the University of New South Wales to design a personalized mRNA vaccine for his rescue dog, Rosie. After receiving the experimental vaccine, the dog's tumors shrank significantly and her condition improved, though she was diagnosed with mast cell skin cancer rather than melanoma.

the-scientist.comjapantimes.co.jpindependent.co.ukunsw.edu.au

1:53:55Rhonda Patrick (host)corroborated (web)

A computational model identified mutations in the Yamanaka factors that increased the efficiency of induced pluripotency by 50-fold.

"What do you think of the new data that came out using this this model called GPT-4b micro, GPT micro 4B, um, where I guess there's this model that was used to figure out how to make certain mutations in the four different Yamanaka factors to make them more effective? So they were able to basically 50-fold more, um, be more effective or efficient at increasing this induced pluripotency." (said at 1:53:55)

No published record matching the claim that a computational model identified mutations in the Yamanaka factors to increase reprogramming efficiency by 50-fold was located; this does not prove the claim false.

corroborated by web sources

In August 2025, OpenAI and Retro Biosciences reported that using an AI model adapted for protein engineering, GPT-4b micro, they designed novel variants of Yamanaka factors (such as SOX2 and KLF4). In laboratory testing, these redesigned proteins produced a greater than 50-fold increase in the expression of stem cell reprogramming markers compared to standard wild-type factors.

endpoints.newspristines.comopenai.com

2

No source found (not proven false)

0:44:05Derya Unutmazunverifiedvery low

A recent study published in Science found that the OpenAI o1 preview model performed significantly better than the average doctor in diagnosing medical conditions.

"Uh in fact, uh a Science paper came out recently, which was done with o1 preview model, which is a very old model... And um and they found that o1 model uh did did better than average doctor in diagnosing, like significantly better. They did didn't miss." (said at 0:44:05)

No published record matching a study in Science demonstrating that the OpenAI o1 preview model performed significantly better than the average doctor in diagnosing medical conditions was located; this does not prove the claim false.

1:13:35Derya Unutmazunverifiedvery low

A machine learning study utilizing UK Biobank data from 500,000 participants was able to predict approximately 1,000 diseases before clinical onset.

"There was a study from um UK Biobank. Um UK has this amazing biobank with 500,000 people, uh lots of data sets, incredible data sets. And so and this was actually done I think more than a year ago with models that were a year or two years old. They took a lot of that data, and they were able to predict about thousand diseases before they happened." (said at 1:13:35)

No published record matching the claim that a machine learning model utilizing UK Biobank data predicted approximately 1,000 diseases before onset was located; this does not prove the claim false. While the UK Biobank includes approximately 500,000 participants and has been widely used to train machine learning and multi-omics models for incident disease prediction, published multi-disease prediction models typically evaluate dozens to a few hundred distinct conditions rather than approximately 1,000 individual diseases.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.